Therefore, we assumed that combination of RSV with pharmacological inhibitor of VEGF-B signaling pathway could potentiate the anti-tumor effect of RSV, and would be a promising modality for clinical PaCa therapy. This evidence concerns the gene VEGFB and permanent neonatal diabetes mellitus-pancreatic and cerebellar agenesis syndrome.